Syntara Ltd (ASX:SNT) CEO Gary Phillips joined Jonathan Jackson in the Proactive Australia studio to discuss the company’s recent $10 million capital raise and how this will be applied towards Syntara's drug development strategy. The funds raised will be used towards the completion of three phase 2 clinical trials in myelofibrosis, scarring and iRBD/Parkinson’s disease. Post raise, Syntara will be in a strong financial position after emerging from the restructuring of Pharmaxis and having shed more than A$14 million in costs per annum. Finally, Phillips discusses what the company has planned for 2024.
Syntara raising $10 million to support for three phase 2 clinical trials
